Marianna Mancini - 30 Mar 2023 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Chief Operating Officer
Signature
/s/ Michael Morneau as Attorney-in-Fact
Issuer symbol
VKTX
Transactions as of
30 Mar 2023
Net transactions value
-$862,045
Form type
4
Filing time
03 Apr 2023, 19:22:47 UTC
Previous filing
30 Mar 2023
Next filing
18 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $196,812 +23,100 +8.8% $8.52 284,995 30 Mar 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $76,900 +10,000 +3.5% $7.69 294,995 30 Mar 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $19,410 +3,000 +1% $6.47 297,995 30 Mar 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $614,029 -36,100 -12% $17.01 261,895 30 Mar 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +56,667 +22% $0.000000 318,562 30 Mar 2023 Direct F2
transaction VKTX Common Stock, par value $0.00001 per share Tax liability $541,138 -30,799 -9.7% $17.57 287,763 30 Mar 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (right to buy) Options Exercise $0 -23,100 -100% $0.000000* 0 30 Mar 2023 Common Stock 23,100 $8.52 Direct F1, F4
transaction VKTX Stock Option (right to buy) Options Exercise $0 -10,000 -100% $0.000000* 0 30 Mar 2023 Common Stock 10,000 $7.69 Direct F1, F5
transaction VKTX Stock Option (right to buy) Options Exercise $0 -3,000 -75% $0.000000 1,000 30 Mar 2023 Common Stock 3,000 $6.47 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 66.67% of which vested on April 3, 2023 upon the achievement of two non-financial performance goals.
F3 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units.
F4 25% of the shares subject to the option vested on each one year anniversary of the grant date.
F5 One-third of the shares subject to the option vested on each one year anniversary of the grant date.